Physician profile
Sydney E Mccool
NPI 1063014553
$1,626.17
in general payments reported to CMS, 2019-2025
25 companies · $24.39 in 2025
The $24.39 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $875 · 2023: $95.68 · 2024: $14.45 · 2025: $24.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $281.97 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $267.95 | 2021-2023 | Imbruvica |
| Seagen INC. | $165.27 | 2021-2022 | |
| Puma Biotechnology, INC. | $121.46 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $88.71 | 2022 | |
| Merck Sharp & Dohme LLC | $78.70 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $58.43 | 2022 | |
| Daiichi Sankyo INC. | $53.04 | 2022 | |
| Coherus Oncology, INC. | $50.91 | 2022 | |
| Sobi, INC | $48.61 | 2022 | |
| Eisai INC. | $41.36 | 2022 | |
| Abbvie INC. | $38.84 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.60 | 2021 | |
| Dendreon Pharmaceuticals LLC | $34.90 | 2022 | |
| Taiho Oncology, INC. | $33.01 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.55 | 2021-2022 | |
| Eusa Pharma (US) LLC | $28.39 | 2021 | |
| Octapharma USA, INC. | $24.54 | 2022 | |
| Karyopharm Therapeutics INC. | $24.26 | 2022 | |
| Array Biopharma INC | $22.73 | 2021 | |
| Rigel Pharmaceuticals, INC. | $21.96 | 2022 | |
| Incyte Corporation | $21.46 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.65 | 2022 | |
| Beigene USA, INC. | $16.83 | 2022 | |
| Seqirus USA INC | $16.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Mccool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.